Outlook Therapeutics

OTLK

Biotechnology · Healthcare

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

Outlook Therapeutics is a small biotech company focused on developing a drug to treat serious eye diseases. Its main product is ONS-5010 (branded as LYTENAVA), a form of bevacizumab designed to treat wet age-related macular degeneration, a condition that can cause blindness in older adults. The company targets ophthalmologists and their patients, competing in a market already served by established drugs like Eylea and Lucentis.

The company earns revenue by selling its eye injection drug, though it is still in the very early stages of commercialization and currently spends far more money than it brings in — as shown by its deeply negative margins. It operates primarily in the United States and is a very small player in a crowded field dominated by much larger pharmaceutical companies. The biggest risk it faces is gaining meaningful market share against well-entrenched competitors while managing its limited cash runway to fund ongoing operations.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-99.4% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+72.7% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

34.5%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~4 months

$11M cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Outlook Therapeutics has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

-88.9%

Thin — -88.9% gross margin

Profit after running costs

Operating Margin

-120111.1%

Losing money on operations — -120111.1%

Return on the money invested

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-169.4%

Shrinking sales (-169.4% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

—

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial